Reaction
Cutaneous T-Cell Lymphoma reporting signals
As of the last recalculation, Cutaneous T-Cell Lymphoma appears in 1,172 FAERS reports alongside 26 co-occurring drug terms. The strongest observed disproportionality signal is BRENTUXIMAB VEDOTIN (PRR 86.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Brentuximab Vedotin | 48 | 86.7 | 87.1 |
| Baricitinib | 11 | 20.4 | 20.5 |
| Mupirocin | 14 | 18.6 | 18.7 |
| Mupirocin Calcium | 14 | 18.3 | 18.3 |
| Adalimumab-Fkjp | 45 | 17.9 | 17.9 |
| Adalimumab-Aaty | 45 | 17.5 | 17.5 |
| Adalimumab-Adaz | 45 | 15.7 | 15.7 |
| Dupilumab | 314 | 15.4 | 15.5 |
| Upadacitinib | 58 | 13.2 | 13.3 |
| Ustekinumab | 69 | 12.7 | 12.7 |
| Melphalan | 16 | 12.7 | 12.7 |
| Melphalan Hydrochloride | 16 | 11.5 | 11.5 |
| Triamcinolone Acetonide Ointment Usp, 0.05% | 14 | 10.7 | 10.7 |
| Ixekizumab | 18 | 8.8 | 8.8 |
| Brexpiprazole | 8 | 8.6 | 8.6 |
| Etoposide | 31 | 7.7 | 7.7 |
| Ifosfamide | 9 | 7.5 | 7.5 |
| Daratumumab | 16 | 7.2 | 7.2 |
| Gemcitabine | 15 | 6.8 | 6.8 |
| Secukinumab | 58 | 6.7 | 6.7 |
| Guselkumab | 13 | 6.5 | 6.5 |
| Risankizumab-Rzaa | 26 | 5.8 | 5.8 |
| Carfilzomib | 8 | 5.1 | 5.1 |
| Benralizumab | 5 | 4.5 | 4.5 |
| Bimekizumab | 5 | 4.2 | 4.2 |
| Apremilast | 33 | 4.1 | 4.1 |